ジェネリックがん治療薬の世界市場レポート 2025年

ジェネリックがん治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.0％で381億6,000万米ドルに成長します。予測期間の成長は、バイオシミラーの承認、競合の増加、遠隔医療と遠隔診療、オーダーメイド治療のパラダイム、価格圧力に起因すると考えられます。予測期間の主な動向としては、ファーマコビジランスの強化、規制の合理化、併用療法の重視、高精度ジェネリック腫瘍薬、市場アクセスの拡大などが挙げられます。

ジェネリックがん治療薬市場の成長は、がん患者の大幅な増加によって促進されると予想されます。がんは、さまざまな臓器に影響を及ぼす制御不能な細胞増殖を特徴とし、重大な罹患率と死亡率を伴う世界の健康上の大きな課題となっています。費用対効果の高いジェネリックがん治療薬を利用できることは、がん治療にとって極めて重要であり、必要不可欠な治療法へのアクセスを強化し、市場競争を促進し、ヘルスケアコストを削減します。2022年1月の米国国立がん研究所（NCI）によると、米国人口の約5.4％、1,810万人ががんサバイバーでした。さらに、623,405人が転移性がんに罹患しており、2025年には693,452人に増加すると予測されています。その結果、がん患者の大幅な増加がジェネリックがん治療薬市場の成長の原動力となっています。

個別化医療に対する需要の高まりが、今後のジェネリックがん治療薬市場拡大の原動力になると予測されています。個別化医療とは、各患者固有の遺伝的、環境的、ライフスタイル的要因に基づいて治療や介入をカスタマイズする、急速に進歩する医療アプローチです。ジェネリックがん治療薬は、個々の患者のニーズに対応した費用対効果の高い選択肢を提供し、ターゲットを絞った専門的ながん治療への幅広いアクセスを促進することで、個別化医療において重要な役割を果たしています。例えば、2024年2月、米国の非営利団体である個別化医療連合（PMC）が発表したデータによると、2023年にFDAが承認した希少疾患に対する新たな個別化治療は16件で、2022年のわずか6件から大幅に増加しました。このように、個別化医療に対する需要の高まりがジェネリックがん治療薬市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ジェネリックがん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のジェネリックがん治療薬市場：成長率分析
• 世界のジェネリックがん治療薬市場の実績：規模と成長, 2019-2024
• 世界のジェネリックがん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界ジェネリックがん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のジェネリックがん治療薬市場分子タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 巨大分子
• 小分子
• 世界のジェネリックがん治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 世界のジェネリックがん治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• マネージドケア機関
• 世界のジェネリックがん治療薬市場、巨大分子のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 生物学的製剤
• バイオシミラー
• 世界のジェネリックがん治療薬市場、小分子のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 標的治療薬
• ホルモン療法薬

第7章 地域別・国別分析

• 世界のジェネリックがん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のジェネリックがん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ジェネリックがん治療薬市場：競合情勢
• ジェネリックがん治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• Fresenius Kabi AG
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Merck & Co. Inc.
• Baxter International Inc.
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited
• Cipla Inc.
• Hikma Pharmaceuticals
• Endo Pharmaceuticals Inc.
• Aspen Pharmacare Holdings Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ジェネリックがん治療薬市場2029：新たな機会を提供する国
• ジェネリックがん治療薬市場2029：新たな機会を提供するセグメント
• ジェネリックがん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Generic oncology drugs are medications designed for cancer treatment, produced by different pharmaceutical companies after the expiration of patent protection for the original brand-name drug. These generic drugs contain identical active ingredients and share the same dosage forms, strength, route of administration, and intended use as the original brand-name drug.

Generic oncology drugs encompass two main types of molecules large molecules and small molecules. Large molecules, also known as biologics, are intricate molecules derived from living organisms, such as proteins, antibodies, or nucleic acids. Trastuzumab (Herceptin), an example of a large molecule-based generic oncology drug, is utilized in cancer treatment by targeting specific proteins or receptors on cancer cells. These drugs can be administered through oral and parenteral routes and are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and managed care institutions.

The generic oncology drugs research report is one of a series of new reports from The Business Research Company that provides generic oncology drugs market statistics, including the generic oncology drugs industry's global market size, regional shares, competitors with a generic oncology drugs market share, detailed generic oncology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the generic oncology drugs industry. This generic oncology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The generic oncology drugs market size has grown strongly in recent years. It will grow from $27.24 billion in 2024 to $29.15 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to patent expirations, healthcare cost containment, increased cancer prevalence, health insurance coverage, physician prescribing practices

The generic oncology drugs market size is expected to see strong growth in the next few years. It will grow to $38.16 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to biosimilar approvals, increased competition, telemedicine and remote care, tailored treatment paradigm, pricing pressure. Major trends in the forecast period include increased pharmacovigilance, regulatory streamlining, combination therapy focus, precision generic oncology medications, expanded market access.

The anticipated growth in the generic oncology drugs market is expected to be propelled by a significant increase in cancer patients. Cancer, characterized by uncontrolled cell growth impacting various organs, poses a considerable global health challenge with significant morbidity and mortality. The availability of cost-effective generic oncology drugs is crucial for cancer treatment, enhancing access to essential therapies, fostering market competition, and reducing healthcare costs. According to the National Cancer Institute (NCI) in January 2022, approximately 5.4% of the US population, equivalent to 18.1 million individuals, were cancer survivors. Moreover, 623,405 people were living with metastatic cancer types, projected to increase to 693,452 by 2025, emphasizing the growing impact of cancer. Consequently, the significant rise in cancer patients is a driving force behind the growth of the generic oncology drugs market.

The growing demand for personalized medicine is anticipated to drive the expansion of the generic oncology drugs market in the future. Personalized medicine is a rapidly advancing medical approach that customizes treatments and interventions based on the unique genetic, environmental, and lifestyle factors of each patient. Generic oncology drugs play a crucial role in personalized medicine by offering cost-effective alternatives that cater to individual patient needs and promoting wider access to targeted and specialized cancer therapies. For example, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, indicated that in 2023, the FDA approved 16 new personalized treatments for rare diseases, a significant rise from just six approvals in 2022. Thus, the increasing demand for personalized medicine is propelling the growth of the generic oncology drugs market.

A notable trend is the emergence of novel formulations, which major companies are actively pursuing in the generic oncology drugs market. These companies are concentrating on the development of innovative drug delivery systems, modified-release formulations, and alternative dosage forms to enhance patient compliance and maintain their market standing. For example, in January 2023, MSN Laboratories Private Limited, an India-based pharmaceutical company specializing in generic drugs, introduced Palborest, the world's first generic Palbociclib tablets for advanced breast cancer treatment. This generic breast cancer drug provides a cost-effective alternative to the innovator tablet while ensuring bioequivalence. Its tablet form offers advantages over capsules, allowing administration with or without food and co-administration with proton pump inhibitors or antacids. Moreover, the tablet formulation is lactose- and gelatin-free, contributing to the drug's efficacy.

Major players in the generic oncology drugs market are intensifying efforts to introduce high-quality treatment options such as Bortezomib to enhance their competitive position. Bortezomib, a proteasome inhibitor used for multiple myelomas and certain lymphomas, inhibits cancer cell growth, thereby improving therapeutic outcomes. For instance, in May 2022, Gland Pharma, an India-based company, launched the generic cancer treatment drug Bortezomib in the US market. This drug, therapeutically equivalent to Takeda Pharmaceuticals' product, aims to offer an affordable and high-quality treatment alternative for US patients.

In March 2023, Pfizer Inc., a US-based pharmaceutical and biotechnology company, completed the acquisition of Seagen Inc. for $43 billion. This strategic move aligns with Pfizer's goal to reinforce its market presence as a prominent player in the oncology sector. By incorporating Seagen's diverse range of medicines, Pfizer significantly strengthens and complements its existing oncology portfolio. Seagen Inc. is a US-based manufacturer of brentuximab vedotin (ADCETRIS), a cancer drug.

Major companies operating in the generic oncology drugs market include Pfizer Inc., AbbVie, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Fresenius Kabi AG, GlaxoSmithKline PLC, Eli Lilly and Company, Merck & Co. Inc., Baxter International Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Inc., Hikma Pharmaceuticals, Endo Pharmaceuticals Inc., Aspen Pharmacare Holdings Limited, Lupin Limited, Towa Pharmaceutical Co Ltd, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Accord Healthcare

North America was the largest region in the generic oncology drugs market in 2024. The regions covered in the generic oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the generic oncology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The generic oncology drugs market consists of sales of paclitaxel, cyclophosphamide, gemcitabine, and fluorouracil. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Generic Oncology Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on generic oncology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for generic oncology drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The generic oncology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Molecule Type: Large Molecule; Small Molecule
• 2) By Route Of Administration: Oral; Parenteral
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Managed Care Institutions
• Subsegments:
• 1) By Large Molecule: Monoclonal Antibodies; Biologics; Biosimilars
• 2) By Small Molecule: Chemotherapeutics; Targeted Therapy Agents; Hormonal Therapy Drugs
• Companies Mentioned: Pfizer Inc.; AbbVie; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca Plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Generic Oncology Drugs Market Characteristics

3. Generic Oncology Drugs Market Trends And Strategies

4. Generic Oncology Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Generic Oncology Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Generic Oncology Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Generic Oncology Drugs Market Growth Rate Analysis
• 5.4. Global Generic Oncology Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Generic Oncology Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Generic Oncology Drugs Total Addressable Market (TAM)

6. Generic Oncology Drugs Market Segmentation

• 6.1. Global Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Large Molecule
• Small Molecule
• 6.2. Global Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.3. Global Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Managed Care Institutions
• 6.4. Global Generic Oncology Drugs Market, Sub-Segmentation Of Large Molecule, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Biologics
• Biosimilars
• 6.5. Global Generic Oncology Drugs Market, Sub-Segmentation Of Small Molecule, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapeutics
• Targeted Therapy Agents
• Hormonal Therapy Drugs

7. Generic Oncology Drugs Market Regional And Country Analysis

• 7.1. Global Generic Oncology Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Generic Oncology Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Generic Oncology Drugs Market

• 8.1. Asia-Pacific Generic Oncology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Generic Oncology Drugs Market

• 9.1. China Generic Oncology Drugs Market Overview
• 9.2. China Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Generic Oncology Drugs Market

• 10.1. India Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Generic Oncology Drugs Market

• 11.1. Japan Generic Oncology Drugs Market Overview
• 11.2. Japan Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Generic Oncology Drugs Market

• 12.1. Australia Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Generic Oncology Drugs Market

• 13.1. Indonesia Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Generic Oncology Drugs Market

• 14.1. South Korea Generic Oncology Drugs Market Overview
• 14.2. South Korea Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Generic Oncology Drugs Market

• 15.1. Western Europe Generic Oncology Drugs Market Overview
• 15.2. Western Europe Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Generic Oncology Drugs Market

• 16.1. UK Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Generic Oncology Drugs Market

• 17.1. Germany Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Generic Oncology Drugs Market

• 18.1. France Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Generic Oncology Drugs Market

• 19.1. Italy Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Generic Oncology Drugs Market

• 20.1. Spain Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Generic Oncology Drugs Market

• 21.1. Eastern Europe Generic Oncology Drugs Market Overview
• 21.2. Eastern Europe Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Generic Oncology Drugs Market

• 22.1. Russia Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Generic Oncology Drugs Market

• 23.1. North America Generic Oncology Drugs Market Overview
• 23.2. North America Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Generic Oncology Drugs Market

• 24.1. USA Generic Oncology Drugs Market Overview
• 24.2. USA Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Generic Oncology Drugs Market

• 25.1. Canada Generic Oncology Drugs Market Overview
• 25.2. Canada Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Generic Oncology Drugs Market

• 26.1. South America Generic Oncology Drugs Market Overview
• 26.2. South America Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Generic Oncology Drugs Market

• 27.1. Brazil Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Generic Oncology Drugs Market

• 28.1. Middle East Generic Oncology Drugs Market Overview
• 28.2. Middle East Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Generic Oncology Drugs Market

• 29.1. Africa Generic Oncology Drugs Market Overview
• 29.2. Africa Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Generic Oncology Drugs Market Competitive Landscape And Company Profiles

• 30.1. Generic Oncology Drugs Market Competitive Landscape
• 30.2. Generic Oncology Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

31. Generic Oncology Drugs Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Fresenius Kabi AG
• 31.3. GlaxoSmithKline PLC
• 31.4. Eli Lilly and Company
• 31.5. Merck & Co. Inc.
• 31.6. Baxter International Inc.
• 31.7. Mylan N.V.
• 31.8. Sun Pharmaceutical Industries Ltd.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Dr. Reddy's Laboratories Ltd.
• 31.11. Aurobindo Pharma Limited
• 31.12. Cipla Inc.
• 31.13. Hikma Pharmaceuticals
• 31.14. Endo Pharmaceuticals Inc.
• 31.15. Aspen Pharmacare Holdings Limited

32. Global Generic Oncology Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Generic Oncology Drugs Market

34. Recent Developments In The Generic Oncology Drugs Market

35. Generic Oncology Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Generic Oncology Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Generic Oncology Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Generic Oncology Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer